Results
Jagsonpal Pharmaceuticals Q1 FY27 Revenue Up 9%
Jagsonpal reported Q1 FY27 revenue growth of 9% YoY, with PAT surging 22% and EBITDA margins expanding 240 bps to 23%.
The company completed the strategic acquisition of Aequitas Healthcare for ₹20.8
